ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults

ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults 2 April 2025 Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased important antiviral host-defence pathways Pre-clinical data demonstrated reduced influenza virus dissemination to the lungs of aged mice, consistent with results from studies in younger animals Data published in ERJ Open Research, a leading open access journal in respiratory medicine Melbourne, Australia, 2 April 2025 – ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral respiratory infections, announces today the early view publication of results of a Phase I extension study in older adults (66-80) of its liquid formulation of INNA-051, a novel TLR2/6 agonist, in ERJ Open Research, a leading research journal of the European Respiratory Society 1 In a placebo-controlled dose-escalation Phase 1 study, a cohort of healthy older volunteers (66 – 80 years) received repeated intranasal doses of INNA-051. Biomarker analysis showed that INNA-051 triggered host defence pathways within eight hours of each dose. INNA-051 was also well-tolerated. The publication also includes supportive preclinical data. Dosing of INNA-051 in aged mice challenged with H3N2 seasonal influenza virus was shown to stimulate natural nasopharyngeal host defences and resulted in reduced viral dissemination to the lungs.

The release as fetched from its publisher. enarespiratory.com ↗